Table 2 Patient characteristics for breast cancer intrinsic subtypes defined by four biomarkers a
Luminal A and luminal B (N = 916) | HER2-enriched (N = 151) | Triple-negative (N = 182) | |||||||
|---|---|---|---|---|---|---|---|---|---|
Characteristics | Ki-67 <14% (N = 540) | Ki-67 ≥14% (N = 376) | P b | Ki-67 <14% (N = 42)c | Ki-67 ≥14% (N = 107)c | P b | Ki-67 <14% (N = 38)d | Ki-67 ≥14% (N = 143)d | P b |
Age (years), n (%) | |||||||||
<40 | 33 (6.1) | 32 (8.5) | NS | 4 (9.5) | 15 (14.0) | NS | 5 (13.2) | 22 (15.4) | NS |
40 to 55 | 197 (36.5) | 139 (37.1) | 14 (33.3) | 49 (45.8) | 9 (23.7) | 58 (40.6) | |||
>55 | 310 (57.3) | 205 (54.4) | 24 (57.1) | 43 (40.2) | 24 (63.2) | 63 (44.1) | |||
Menopausal status, n (%) | |||||||||
Premenopausal | 172 (31.9) | 130 (34.7) | NS | 15 (35.7) | 53 (49.5) | NS | 12 (31.6) | 59 (41.3) | NS |
Postmenopausal | 360 (66.6) | 242 (64.3) | 26 (61.9) | 54 (50.5) | 26 (68.4) | 83 (58.0) | |||
NA | 8 (1.5) | 4 (1.1) | 1 (2.4) | – | – | 1 (0.7) | |||
Tumor size (cm), n (%) | |||||||||
<2 | 250 (46.4) | 158 (42.1) | NS | 14 (33.3) | 29 (27.1) | NS | 8 (21.1) | 36 (25.2) | NS |
2 to 5 | 261 (48.2) | 198 (52.5) | 23 (54.8) | 67 (62.6) | 27 (71.1) | 89 (62.2) | |||
>5 | 22 (4.1) | 14 (3.7) | 4 (9.5) | 10 (9.3) | 1 (2.6) | 13 (9.1) | |||
NA | 7 (1.3) | 6 (1.6) | 1 (2.4) | 1 (0.9) | 2 (5.3) | 5 (3.5) | |||
Tumor grade, n (%) | |||||||||
1 | 144 (26.7) | 39 (10.4) | <0.0001 | 2 (4.8) | 2 (1.9) | 0.0036 | 1 (2.6) | 1 (0.7) | 0.003 |
2 | 311 (57.5) | 226 (60.0) | 27 (64.3) | 43 (40.2) | 19 (50.0) | 38 (26.6) | |||
3 | 47 (8.7) | 91 (24.3) | 10 (23.8) | 55 (51.4) | 13 (34.2) | 90 (62.9) | |||
NA | 38 (7.1) | 20 (5.3) | 3 (7.1) | 7 (6.5) | 5 (13.2) | 14 (9.8) | |||
Lymph nodes, n (%) | |||||||||
0 | 293 (54.2) | 192 (50.9) | NS | 15 (35.7) | 48 (44.9) | NS | 13 (34.2) | 77 (53.8) | NS |
1 to 3 | 145 (26.9) | 109 (29.1) | 16 (38.1) | 28 (26.2) | 13 (34.2) | 36 (25.2) | |||
≥4 | 101 (18.7) | 73 (19.5) | 11 (26.2) | 30 (28.0) | 11 (28.9) | 27 (18.9) | |||
NA | 1 (0.2) | 2 (0.5) | – | 1 (0.9) | 1 (2.6) | 3 (2.1) | |||
Chemotherapy, n (%) | |||||||||
No | 275 (50.8) | 174 (46.1) | NS | 10 (23.8) | 27 (25.2) | NS | 9 (23.7) | 20 (14.0) | NS |
Yes | 260 (48.2) | 199 (53.1) | 31 (73.8) | 79 (73.8) | 29 (76.3) | 121 (84.6) | |||
NA | 5 (0.9) | 3 (0.8) | 1 (2.4) | 1 (0.9) | – | 2 (1.4) | |||
Hormonotherapy, n (%) | |||||||||
No | 106 (19.5) | 67 (17.6) | NS | 22 (52.4) | 45 (42.1) | NS | 19 (50.0) | 100 (69.9) | NS |
Yes | 432 (80.1) | 307 (81.9) | 20 (47.6) | 62 (57.9) | 19 (50.0) | 43 (30.1) | |||
NA | 2 (0.4) | 2 (0.5) | – | – | – | – | |||
Local therapy, n (%) | |||||||||
Mastectomy alone | 172 (31.9) | 105 (28.0) | 19 (45.2) | 30 (28.0) | 20 (52.6) | 36 (25.2) | |||
Mastectomy + RT | 61 (11.3) | 36 (9.6) | NS | 7 (16.7) | 16 (15.0) | NS | 7 (18.4) | 23 (16.1) | NS |
Lumpectomy alone | 28 (5.2) | 13 (3.5) | 1 (2.4) | 8 (7.5) | – | 5 (3.5) | |||
Lumpectomy + RT | 279 (51.6) | 222 (58.9) | 15 (35.7) | 53 (49.5) | 11 (28.9) | 79 (55.2) | |||